At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects
In Brief
A Phase 3 clinical trial evaluating Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, and 1 other intervention for Influenza. Completed, enrolled 11,404 participants across 56 sites in 3 countries.
Detailed Summary
The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age.
Study Details
Timeline
Interventions
One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.
One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
One dose (0.5 mL) of phosphate buffered solution.